Kai Tsao, System Head of Solid Tumor, Medical Director of Zuckerberg Cancer Center and Medical Oncology Prostate Cancer Program at the Northwell Health Cancer Institute, shared Great Debates’ post on LinkedIn, adding:
“How early should we use Lu – 177 for patients with advanced prostate cancer? Looking forward to a great discussion with our expert faculty panel!”
Quoting Great Debates’ post:
“System Chief of the Division of Solid Tumor Oncology at Northwell Cancer Institute, Kai Tsao, MD MS shares why he’s excited to join us at OLN Great Debates in Solid Tumors.
A recognized leader in genitourinary oncology and prostate cancer care, he will debate when to bring lutetium – PSMA radioligand therapy into metastatic prostate cancer care and whether earlier use offers an advantage over later – line treatment.”
More about the debate
More posts featuring Kai Tsao and Great Debates